Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07574489
PHASE2/PHASE3

Whole Versus Partial Gland Boost During Prostate SBRT

Sponsor: University of Nebraska

View on ClinicalTrials.gov

Summary

This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.

Official title: A Phase 2/3 Randomized Trial of Whole Versus Partial Gland Boost During Prostate Stereotactic Body Radiotherapy (SBRT)

Key Details

Gender

MALE

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

186

Start Date

2026-07-25

Completion Date

2035-08-25

Last Updated

2026-05-13

Healthy Volunteers

No

Interventions

RADIATION

Prostate stereotactic body radiotherapy with whole gland boost

External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost

RADIATION

Prostate stereotactic body radiotherapy with DIL boost

External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion.

Locations (1)

Fred & Pamela Buffet Cancer Center

Omaha, Nebraska, United States